SyndicationMar082011
04:36:05 pm
04:36:05 pm
Generic Cytotec
Cytotec conducting a
randomized controlled study in USA, which included patients with rheumatoid
arthritis who have risk factors for NSAID-induced gastropathy (gastric and
duodenal history) and continue to receive NSAIDs, following results were
obtained [53]. By the end of the study established the presence of the ulcer in
8% of patients taking famotidine 40 mg, and 15% - are using lansoprazole 15 mg
/ day. Thus, the standard dose of famotidine may be used for the prevention of
NSAID-induced ulcers of the stomach and duodenum in patients with rheumatoid
arthritis c, with a history of uncomplicated ulcer.
http://www.ghihotels.com/hgc/displaynews.aspx?id=113
In a prospective randomized double-blind, placebo-controlled study comparing two parallel groups investigated the use of pantoprazole for the prevention of http://www.ghihotels.com/hgc/displaynews.aspx?id=113 in patients with diseases of the joints (rheumatoid arthritis or osteoarthritis) and continue taking NSAIDs [27]. All patients at the time of initiation of pantoprazole and placebo had no gastroduodenal ulcers, but are allowed no more than 10 erosions, submucosal hemorrhages, or petechiae in the stomach and duodenum. Completed the 12-week study 95 people. Established that pantoprazole (Cytotec 200 mcg / day) can be used for the prevention of NSAID-induced ulcers in patients with diseases of the joints, continuing to take NSAIDs and have intact mucosa. In the presence of erosions, submucosal hemorrhages, or petechiae efficacy of pantoprazole for the prevention of Cytotec ulcers was not credible, compared with placebo. Evaluating the effectiveness of http://www.ghihotels.com/hgc/displaynews.aspx?id=113 in the prevention of NSAID-induced ulcers in elderly H. pylori-positive patients who have risk factors, conducted in a randomized, placebo-controlled study [55]. Individuals included in the study had ulcer history and ulcer defect was absent at the time of inspection. All patients received NSAIDs within 4 weeks. One month of receiving pantoprazole was more effective than weekly antigelikobakterna therapy on the basis of pantoprazole in the prevention of NSAID-induced gastroduodenal ulcers in elderly H. pylori-positive patients taking NSAIDs.
http://www.ghihotels.com/hgc/displaynews.aspx?id=113
http://www.ghihotels.com/hgc/displaynews.aspx?id=113
In a prospective randomized double-blind, placebo-controlled study comparing two parallel groups investigated the use of pantoprazole for the prevention of http://www.ghihotels.com/hgc/displaynews.aspx?id=113 in patients with diseases of the joints (rheumatoid arthritis or osteoarthritis) and continue taking NSAIDs [27]. All patients at the time of initiation of pantoprazole and placebo had no gastroduodenal ulcers, but are allowed no more than 10 erosions, submucosal hemorrhages, or petechiae in the stomach and duodenum. Completed the 12-week study 95 people. Established that pantoprazole (Cytotec 200 mcg / day) can be used for the prevention of NSAID-induced ulcers in patients with diseases of the joints, continuing to take NSAIDs and have intact mucosa. In the presence of erosions, submucosal hemorrhages, or petechiae efficacy of pantoprazole for the prevention of Cytotec ulcers was not credible, compared with placebo. Evaluating the effectiveness of http://www.ghihotels.com/hgc/displaynews.aspx?id=113 in the prevention of NSAID-induced ulcers in elderly H. pylori-positive patients who have risk factors, conducted in a randomized, placebo-controlled study [55]. Individuals included in the study had ulcer history and ulcer defect was absent at the time of inspection. All patients received NSAIDs within 4 weeks. One month of receiving pantoprazole was more effective than weekly antigelikobakterna therapy on the basis of pantoprazole in the prevention of NSAID-induced gastroduodenal ulcers in elderly H. pylori-positive patients taking NSAIDs.
http://www.ghihotels.com/hgc/displaynews.aspx?id=113
Good continuation